We investigated the binding characteristics of angiotensin receptors and used this assay to determine the predominant enzyme capable of converting angiotensin I in the human left ventricle. 125 I-angiotensin IV binding sites could be detected in the human left ventricle. Using competitive radioligand binding assays, we were able to demonstrate that the chymase/cathepsin G enzyme inhibitor chymostatin was more potent than the angiotensinconverting enzyme (ACE) inhibitor captopril at inhibiting the conversion of angiotensin I in the human left ventricle. Aprotonin (an inhibitor of cathepsin G but of not chymase) had no effect on angiotensin I conversion, suggesting that the majority of the conversion was mediated by chymase. Thus, although the current therapies used for the renin-angiotensin system have focused on ACE inhibitors and AT 1 receptor antagonists, the left ventricle of the human heart expresses mainly AT 2 receptors and the tissue-specific conversion of angiotensin I occurs predominantly via chymase rather than ACE.
INTRODUCTION
The biological actions mediated by the octapeptide angiotensin II are widespread, diverse and play a vital role in cardiovascular homoeostasis. The major components of the renin-angiotensin system are present in peripheral tissues, including the human heart [1] . Angio-greater in the atrium than in the ventricle [1] . The positive inotropic actions of angiotensin II in the atrium (but not in the ventricle) occur via the AT " receptor [6] , while the AT # receptor mediates negative chronotropic actions and is involved in the induction of apoptosis [7] . The AT " receptors are down-regulated and the AT # receptors are up-regulated in failing human hearts [8] .
Angiotensin-converting enzyme (ACE) and two serine proteases, chymase and cathepsin G, have been implicated in the conversion of angiotensin I into angiotensin II [9] . Conflicting results have been reported regarding the principal enzyme involved in the tissue-specific conversion of angiotensin I in the human heart. While some authors have suggested chymase to be the predominant enzyme for the local conversion of angiotensin I [10] [11] [12] , others have suggested ACE [13, 14] . The localization of ACE in the human heart has been confined mainly to the interstitial fluid, myocytes and fibroblasts, whereas chymase is found in mast cells [15] . Furthermore, within the chambers of the heart, there is differential expression of chymase and ACE [16] . Under physiological and pathophysiological conditions mast cells must undergo degranulation to release chymase. Various immunological and non-immunological stimuli can activate mast cell degranulation, including bacterial proteins and complement activation [17] . The continuous generation of angiotensin II in the presence of ACE inhibitor therapy, as a result of serine protease activity, maybe of significance under these pathophysiological conditions.
In the present study we determined the characteristics of "#&I-[Sar",Ile)]angiotensin II binding to angiotensin II receptors in normal human left ventricle. We used this ligand to determine the potential of endogenous cardiac enzymes to convert angiotensin I locally into smaller biologically active peptides that can compete with the binding of and alter the affinity for the ligand at angiotensin receptors. With this method it was possible to detect lower levels of peptide resulting from the conversion of angiotensin I than is possible using HPLC. We measured the ability of enzymic inhibitors of ACE (captopril) and chymase (chymostatin) in this assay to elucidate the predominant pathway of conversion in these tissues.
MATERIALS AND METHODS

Tissue collection
Collection of human tissue was carried out with approval from the local ethics committees. Human left ventricular tissues were obtained from histologically normal hearts not required for further transplantation (from three female and one male donor ; 24-34 years old). None of the donors were receiving pre-operative ACE inhibitor therapy or AT "
antagonists.
Human left ventricle homogenate preparation
The left ventricular free wall of the human heart was homogenized in buffer (20 mM NaH # PO % buffer, pH 7.4, at 4 mC) using a Polytron (Kinematica A. G., Lucerne, Switzerland) at setting 8 for 15 s. The homogenates were centrifuged at 40 000 g for 20 min at 4 mC. The resulting supernatant was discarded and the pellet was resuspended in fresh homogenization buffer and respun as described above. The tissues were rehomogenized and resuspended three times as described above, and the final pellet was resuspended in buffer containing 50 mM NaH # PO % , pH 7.4 (4 mC), 100 mM NaCl and 10 mM MgCl # . The concentration of protein was determined (Bio-Rad Laboratories, Hemel Hempstead, Herts., U.K.) and membrane aliquots were stored at k70 mC until required. In order to preserve any endogenous enzymic activity, we did not include any protease inhibitors in the homogenization buffer.
Kinetic studies
Association studies were carried out in buffer containing 0.2 nM "#&I-[Sar",Ile)]angiotensin II. Homogenates were incubated for increasing time periods (0-180 min). For dissociation experiments, homogenate protein was allowed to incubate for 60 min before aliquots were removed at time intervals and counted for bound radioactivity. Non-specific binding was defined by 1 µM angiotensin II.
Saturation and competition binding assays
Membranes were thawed and suspended in assay buffer containing 50 mM NaH # PO % , pH 7.4 (23 mC), containing 100 mM NaCl, 1 mM EGTA, 10 mM MgCl For competition experiments, homogenate aliquots of 0.6 mg\ml were added to assay tubes containing 0.2 nM "#&I-[Sar",Ile)]angiotensin II and increasing concentrations of competing ligand (1 pM-100 µM). Nonspecific binding was determined by the incubation of 1 µM angiotensin II. The tubes were incubated for 60 min at 23 mC, after which the binding reaction was terminated by rapid vacuum filtration using a Brandell cell harvester and Whatman GF\B filters (SEMAT, St. Albans, Herts., U.K.) which were pre-soaked in wash buffer, comprising 50 mM NaH # PO % , pH 7.4 (4 mC). The filtrates were washed three times and the radioactivity retained on the filter was assayed by γ-counting at an efficiency of 80 %.
Competition binding assays in the presence of enzyme inhibitors
Competition binding studies with angiotensin I and angiotensin II were performed in the presence of 30 µM captopril [10, 11, 14] or 10 µM chymostatin [16] , concentrations calculated to inhibit 95 % of enzymic activity in tubes containing 0.6 mg\ml membrane protein and 0.2 nM "#&I-[Sar",Ile)]angiotensin II. The tubes were left to equilibrate for 60 min at 23 mC and the reaction was terminated as described above.
I-Angiotensin IV binding to human left ventricle
To determine the possibility of the existence of angiotensin type IV (AT % ) receptors in the human heart, homogenate aliquots of 0.6 mg\ml were added to assay tubes containing 0.2 nM "#&I-angiotensin IV (NEN Life Sciences). Non-specific binding was defined by the addition of 1 µM angiotensin IV. The tubes were incubated for 90 min at 23 mC and the reaction was terminated by rapid vacuum filtration as described above.
Data analysis
The results from binding experiments were analysed using the KELL suite of programs (Biosoft, Cambridge, U.K.). All values are expressed as meanspS.E.M. Individual saturation and competition binding experiments were analysed with EBDA [18] to obtain initial estimates. The resulting data files were co-analysed with LIGAND [19] to obtain values of binding affinity (K D ) and receptor density (B max ; expressed as fmol:mg −" protein). In competition and saturation experiments, the presence of one, two or three sites was determined using the F-ratio test in LIGAND. The model adopted was that which provided the significantly best fit (P 0.05). Values of affinity were compared using the Mann-Whitney U test with a significance level of P 0.05. 
RESULTS
Kinetic studies
The angiotensin II receptor antagonist "#&I-[Sar",Ile)]-angiotensin II at a concentration of 0.2 nM bound rapidly and specifically to human left ventricular membranes with an association rate constant (k obs ) of 0.08p 0.002 min −" , and a half-life of association (t " # ) of 9 min (Figure 1 ). The radioligand dissociated with a dissociation rate constant of 0.052p0.001 min −" . The kinetically derived K D of 0.37 nM was comparable with that derived from saturation studies (0.42 nM). 
Competition experiments
Competition experiments were performed using a fixed concentration of 0.2 nM "#&I-[Sar",Ile)]angiotensin II.
The endogenous agonists angiotensin I, angiotensin II and angiotensin III inhibited the specific binding of 0.2 nM "#&I-[Sar",Ile)]angiotensin II in a monophasic manner (Table 1) .
Selectivity was defined by incubating 0.2 nM "#&I- 
Selectivity of captopril and chymostatin in inhibiting the conversion of angiotensin I into angiotensin II in human left ventricle
At a concentration calculated to inhibit 95 % of enzymic activity, the ACE inhibitor captopril at 30 µM did not significantly inhibit the conversion of angiotensin I in the human left ventricle, as determined by the binding parameters (Table 2, Figure 3 ). In contrast, compared with controls, the chymase\cathepsin G inhibitor chymostatin at 10 µM significantly inhibited the local conversion of angiotensin I (P 0.02) (Figure 3) , and also inhibited angiotensin II binding (P 0.05) (Figure 4) . To exclude the possibility that angiotensin I was binding directly to the receptor without further conversion, "#&I-angiotensin I was incubted in the presence of these inhibitors ; binding was not detected (specific binding 9.2p1.1 % ; n l 3 individuals) either at room temperature or at 4 mC. Chymostatin and captopril did not compete for "#&I-[Sar",Ile)]angiotensin II binding sites in this membrane preparation. 
DISCUSSION
This study has shown, using competition binding assays, that an inhibitor of chymase, chymostatin, was more effective than the ACE inhibitor captopril in blocking the conversion of angiotensin I in human heart tissue. These results suggest that the local generation of angiotensin II or other conversion products via chymase may activate angiotensin receptors and could contribute to the physiological or pathophysiological effects of this peptide system.
The binding parameters for the radioligand "#&I- The binding of angiotensin I to the human left ventricle has not been characterized previously. To exclude the possibility that angiotensin I itself was binding to the receptors without further conversion, we used the radiolabelled analogue of this compound ; detectable binding could not be observed at room temperature or at 4 mC, thus indicating the presence of enzymes in homogenates of human left ventricle that were responsible for endogenous conversion.
Previous reports have determined angiotensin I conversion by measuring the generation of angiotensin II by HPLC. We adopted an alternative method and characterized the radioligand binding assay in detail so that we could detect lower levels of peptide resulting from the conversion of angiotensin I than is possible using HPLC. Furthermore, the present assay detects all peptide fragments capable of competing for the radioligand at angiotensin receptors, which may also have functional significance.
Reports to date show conflicting findings with regard to the principal enzyme responsible for the conversion of angiotensin I into angiotensin II. Some authors have described ACE as the predominant enzyme responsible for this conversion in the human heart [13, 14] , while others have postulated chymase as the principal enzyme [10] [11] [12] . The aim of the present study was to clarify if there was any endogenous conversion of angiotensin I in the human left ventricle membrane preparation and, if so, to determine the predominant enzymic pathway responsible for this action. To determine this, we used the ACE inhibitor captopril [23] and the chymase\cathepsin G inhibitor chymostatin [24] . The homogenization buffer did not include any protease inhibitors, thus preserving any endogenous ACE activity. Chymase is found only in mast cells, whereas ACE is found in fibroblasts and cardiac myocytes [15] . Therefore higher levels of ACE than of chymase would be expected to be present in this membrane preparation, favouring ACE-mediated conversion. However, our findings indicate that the chymase\cathepsin G-mediated pathway predominates in the local conversion of angiotensin I in the human left ventricle. Further characterization of these enzymes The chymase-mediated conversion of angiotensin I is predominant over that mediated by ACE. using aprotinin, which is known to inhibit cathepsin G but not chymase, indicated that indeed the majority of the conversion of angiotensin I was mediated by chymase (Scheme 1). This is in agreement with the high levels of chymase-like immunoreactivity that have been reported to be present in the non-diseased left ventricle [16] .
The decrease in the affinity of angiotensin I in the presence of chymostatin was significantly greater than that induced by captopril. Since angiotensin II is converted into angiotensin III, and since the binding affinity is approximately the same for these two peptides where the AT # receptor predominates, one cannot exclude the possibility that aminopeptidases could contribute to the conversion within the human left ventricle and that the binding affinity observed is that of angiotensin III. This is a likely explanation for the reduction in affinity of angiotensin II in the presence of chymostatin. If such high-affinity binding is apparent in the human hearts, angiotensin III may have a functional role.
It has been reported that mast cell carboxypeptidase A can convert angiotensin I into angiotensin-(1-9), and this peptide fragment is an endogenous inhibitor of ACE [14] . With the isolation of novel endogenous ACE inhibitors such as acein-1 [25] and acein-2 [26] , exogenous and endogenous ACE inhibition is probably not as effective as chymase inhibition in preventing the local conversion of angiotensin I in the human heart. Chymase has also been reported to cleave big endothelin-1 to produce novel bioactive endothelin-(1-31) [27] , further enhancing the role of this enzyme in vasoconstrictor peptide biosynthesis. Chymase does not cleave bradykinin [16] , and with ACE inhibitors preserving this vasoactive substance, dual enzyme inhibitor therapy would seem a beneficial approach to the treatment of cardiovascular disorders.
In conclusion, the rank order of inhibitory potency 
